Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical?

María Fernanda Garrido Oyarzún, Camil Castelo-Branco

Resultado de la investigación: Contribución a una revistaReseña científicarevisión exhaustiva

5 Citas (Scopus)

Resumen

Breast cancer is the most prevalent cancer in women and presently, the breast cancer survivors are an important group of women that faced the several consequences of estrogen deficiency, which is especially common in women after chemotherapy. The most bothersome is the vasomotor symptoms, which are effectively relieved by hormonal therapy (HT). Also, the increased risk of osteoporosis and coronary artery disease is major problem to be resolved in pos of maintaining a good quality of life. Fearing cancer recurrence, most physicians do not offer HT to women with a history of breast cancer. Over this issue reviews the available evidence of the use of HT and tibolone in women treated for breast cancer.
Idioma originalInglés estadounidense
Páginas (desde-hasta)10-15
Número de páginas6
PublicaciónGynecological Endocrinology
Volumen33
N.º1
DOI
EstadoPublicada - 2 ene 2017

Palabras clave

  • Breast cancer
  • cancer survivors
  • estrogen–progestin therapy
  • hormone therapy
  • menopausal symptoms
  • tibolone

Huella

Profundice en los temas de investigación de 'Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical?'. En conjunto forman una huella única.

Citar esto